Levi & Korsinsky Issues Reminder to Regeneron Investors on Class Action Lawsuit

Levi & Korsinsky wants to remind investors in Regeneron of the ongoing class action lawsuit with a deadline for lead plaintiff designation set for March 10, 2025. The law firm is urging investors who purchased shares in Regeneron Pharmaceuticals, Inc. to consider participating in the lawsuit if they meet certain criteria.

Regeneron is facing allegations that it made false and misleading statements regarding its drug Eylea, which is used to treat age-related macular degeneration. The lawsuit claims that Regeneron failed to disclose important information about the drug’s potential side effects and risks, leading investors to make decisions based on incomplete or inaccurate information.

Investors who purchased Regeneron stock between July 5, 2017, and April 15, 2020, may be eligible to participate in the class action lawsuit. The lawsuit alleges that Regeneron failed to disclose that Eylea carries a risk of causing certain cardiovascular events, including myocardial infarction, and that the company’s business, operations, and prospects were materially impacted by these undisclosed risks.

According to Levi & Korsinsky, Regeneron investors should be aware of their legal rights and options in this class action lawsuit. The lead plaintiff deadline is approaching, and investors who wish to participate in the lawsuit should act quickly to ensure they meet the necessary requirements and deadlines.

This class action lawsuit against Regeneron highlights the importance of transparency and accurate disclosure in the pharmaceutical industry. Investors rely on companies to provide complete and truthful information about their products and operations to make informed investment decisions.

Investors who believe they may have a claim against Regeneron are encouraged to contact Levi & Korsinsky for more information about the class action lawsuit. The law firm specializes in representing investors in securities litigation and has a track record of success in cases involving allegations of securities fraud and misrepresentation.

As the deadline for lead plaintiff designation approaches, investors in Regeneron should carefully consider their options and take action if they believe they have been harmed by the company’s alleged misconduct. Levi & Korsinsky is committed to holding companies accountable for their actions and helping investors seek justice in cases of securities fraud and misinformation.